Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1/2 3Phase NA 2Phase 3 1Phase 1 1

Status

Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1

Conditions

Prostatic Neoplasms 8Lung Neoplasms 8Triple Negative Breast Neoplasms 5Neoplasm Metastasis 5Multiple Myeloma 5Melanoma 5Carcinoma, Non-Small-Cell Lung 5Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Glioblastoma 4Colorectal Neoplasms 4Urinary Bladder Neoplasms 3Pancreatic Neoplasms 3Glioma 3Fallopian Tube Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Hepatocellular 3Burkitt Lymphoma 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Ovarian Neoplasms 2Oligodendroglioma 2Neuroblastoma 2Meningioma 2Lymphoma, B-Cell 2Endometrial Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Merkel Cell 2Astrocytoma 2Adenocarcinoma of Lung 2

Interventions

Rituximab 16Cyclophosphamide 16Peripheral Blood Stem Cell Transplantation 11fludarabine phosphate 10Cytarabine 9Methotrexate 8Vincristine 7blinatumomab 6Filgrastim 6Etoposide 6fludarabine 5Prednisone 5Mycophenolic Acid 5Lenalidomide 5Dexamethasone 5Cyclosporine 5merphos 4Whole-Body Irradiation 4Radiotherapy 4Ifosfamide 4Carboplatin 4venetoclax 3romidepsin 3prednylidene 3deltacortene 3Spinal Puncture 3Microarray Analysis 3Melphalan 3Magnetic Resonance Spectroscopy 3Inotuzumab Ozogamicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Burkitt Lymphoma × Magnetic Resonance Spectroscopy × Clear all
NCT03504644 2026-05-29

Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

Eastern Cooperative Oncology Group

Phase 1/2 Active not recruiting
40 enrolled 18 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07069699 2026-05-13

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

National Cancer Institute (NCI)

Phase 1/2 Recruiting
50 enrolled
Lymphoid

Burkitt Lymphoma

NCT05936229 2024-07-12

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Fred Hutchinson Cancer Center

Phase 1/2 Withdrawn
Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡